Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30; PMID: 26742998; https://doi.org/10.3322/caac.21332
   PubMed Web of Science ®Google Scholar
• Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer. 2006; 106(7):1624-33; PMID: 16518827; https://doi.org/10.1002/cncr.21778
   PubMed Web of Science ®Google Scholar
• Irving JA, Young RH. Lung carcinoma metastatic to the ovary: a clinicopathologic study of 32 cases emphasizing their morphologic spectrum and problems in differential diagnosis. Am J Surg Pathol. 2005; 29(8):997-1006; PMID: 16006793
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med. 2010; 363(18):1693-703; PMID:20979469; https://doi.org/10.1056/NEJMoa1006448
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, et al. Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009; 27(26):4247-53; PMID:19667264; https://doi.org/10.1200/JCO.2009.22.6993
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25):2385-94; PMID:23724913; https://doi.org/10.1056/NEJMoa1214886
   PubMed Web of Science ®Google Scholar
• Goodwin S, McPherson JD, McCombie WR. Coming of age: Ten years of next-generation sequencing technologies. Nat Rev Genet. 2016; 17(6):333-51; PMID: 27184599; https://doi.org/10.1038/nrg.2016.49
   PubMed Web of Science ®Google Scholar
• Gow C-H, Chang Y-L, Hsu Y-C, Tsai MF, Wu CT, Yu CJ, Yang CH, Lee YC, Yang PC, Shih JY. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol; 2009 Apr; 20(4):696-702; PMID:19088172; https://doi.org/10.1093/annonc/mdn679
   PubMedGoogle Scholar
• Hou L, Ren S, Su B, Zhang L, Wu W, Zhang W, Dong Z, Huang Y, Wu C, Chen G. High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma. J Thorac Dis. 2016; 8(6):1103; PMID: 27293826; https://doi.org/10.21037/jtd.2016.03.96
   PubMed Web of Science ®Google Scholar
• Lung Cancer. N Engl J Med. 2009; 360(1):87-8; PMID:19118313; https://doi.org/10.1056/NEJMc082208
   PubMed Web of Science ®Google Scholar
• Kini SR. Lung cancer Metastatic to other body sites. Color Atlas of Pulmonary Cytopathology: Springer; 2002:141-4.
   Google Scholar
• Yeh K-Y, Chang JW-C, Hsueh S, Chang T-C, Lin M-C. Ovarian metastasis originating from bronchioloalveolar carcinoma: a rare presentation of lung cancer. Jpn J Clin Oncol. 2003; 33(8):404-7; PMID: 14523061; https://doi.org/10.1093/jjco/hyg078
   PubMed Web of Science ®Google Scholar
• Wang W, Wu W, Zhang Y. Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report. Medicine. 2016; 95(30):e4221; PMID: 27472693; https://doi.org/10.1097/MD.0000000000004221
   PubMed Web of Science ®Google Scholar
• Lee KA, Lee JS, Min JK, Kim HJ, Kim WS, Lee KY. Bilateral ovarian metastases from ALK rearranged non-small cell lung cancer. Tuberc Respir Dis (Seoul). 2014; 77(6):258-61; PMID: 25580142; https://doi.org/10.4046/trd.2014.77.6.258
   PubMedGoogle Scholar
• Fujiwara A, Higashiyama M, Kanou T, Tokunaga T, Okami J, Kodama K, Nishino K, Tomita Y, Okamoto I. Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement. Lung Cancer. 2014; 83(2):302-4; PMID: 24360322; https://doi.org/10.1016/j.lungcan.2013.11.022
   PubMed Web of Science ®Google Scholar
• West AH, Yamada SD, MacMahon H, Acharya SS, Ali SM, He J, Lukas RV, Miller VA, Salgia R. Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. Case Rep Clin Pathol. 2014; 1(2):151; PMID: 25541622; https://doi.org/10.5430/crcp.v1n2p151
   PubMedGoogle Scholar
• Choi S, Park CK, Kim SY, Yoon HK, Ro SM, Nam Y. Uterine cervix metastasis in lung adenocarcinoma with Anaplastic Lymphoma Kinase rearrangement. Soonchunhyang Medical Science (SMS). 2015; 21(2):142-5; https://doi.org/10.15746/sms.15.033
   Google Scholar
• Diem S, Früh M, Rodriguez R, Liechti P, Rothermundt C. EML4-ALK-Positive pulmonary adenocarcinoma with an unusual metastatic pattern: A case report. Case Rep Oncol. 2013; 6(2):316-9; PMID: 23898275; https://doi.org/10.1159/000352086
   PubMedGoogle Scholar
• Qiao Y, Ma J-f, Zhang P, Li L. Ovarian metastasis from ALK-positive lung adenocarcinoma: One case report. TUMOR. 2015; 35(7):806-9; https://doi.org/10.3781/j.issn.1000-7431.2015.44.340
   Google Scholar
• Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner DL, et al. Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer. Cancer. 2012; 118(18):4502-11; PMID: 22282022; https://doi.org/10.1002/cncr.27409
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bang Y-J, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13(10):1011-19; PMID: 22954507; https://doi.org/10.1016/S1470-2045(12)70344-3
   PubMed Web of Science ®Google Scholar
• Kim D, Ahn M, Yang P, et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Ann. Oncol. 2012; (23):402-402.
   Google Scholar
• Solomon BJ, Mok T, Kim D-W, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23):2167-77; PMID:25470694; https://doi.org/10.1056/NEJMoa1408440
   PubMed Web of Science ®Google Scholar
• Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013; 31(8):1105-11; PMID: 23401436; https://doi.org/10.1200/JCO.2012.44.5353
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013; 8(7):823-59; PMID:2355237; https://doi.org/10.1097/JTO.0b013e318290868f
   PubMed Web of Science ®Google Scholar
• Tsao M, Hirsch F, Yatabe Y. IASLC atlas of ALK testing in lung cancer. Aurora, CO: IASLC Press. 2013.
   Google Scholar
• Ross JS, Lipson D, Sheehan CE, et al. Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC). Paper presented at: ASCO Annual Meeting Proceedings 2012.
   Google Scholar
• Weickhardt AJ, Aisner DL, Franklin WA, Varella‐Garcia M, Doebele RC, Camidge DR. Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer. Cancer. 2013; 119(8):1467-77; PMID: 23280244; https://doi.org/10.1002/cncr.27913
   PubMed Web of Science ®Google Scholar
• Atherly A, Camidge D. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 2012; 106(6):1100-06; PMID: 22374459; https://doi.org/10.1038/bjc.2012.60
   PubMed Web of Science ®Google Scholar
• Luthra R, Chen H, Roy-Chowdhuri S, Singh RR. Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges. Cancers. 2015; 7(4):2023-36; PMID: 26473927; https://doi.org/10.3390/cancers7040874
   PubMed Web of Science ®Google Scholar